NAD+ injections deliver one molecule that every cell in your body uses
It was first isolated in human plasma in 1973, and subsequent decades of research have revealed a mechanism that goes considerably beyond simple collagen stimulation
Injectable GHK-Cu is classified by the FDA as a Category 2 substance, which restricts its compounding at 503A pharmacies, and it is not FDA-approved for any indication
Quality-Related Safety The most significant safety variable is product quality
It is also used to treat pernicious anemia, vitamin B 12 deficiency (due to low intake from food or inability to absorb due to genetic or other factors), thyrotoxicosis, hemorrhage, malignancy, liver disease and kidney disease
The Realistic Timeline BPC-157 localized effects typically appear within two to four weeks of consistent dosing